MAR 27, 2018 9:00 AM PDT

Proteomics profiling of post-translational modifications in early drug discovery

Speakers

Abstract

DATE: March 27, 2018
TIME: 09:00am PDT, 12:00pm EDT

Advances in mass spectrometry instrumentation and sample handling methods have propelled proteomics and extended its utility for both basic biology and early drug development. Changes in protein abundance and post-translational modification state often reflect the activity of a novel therapeutic agent as well as the sensitivity/resistance of a biological system to treatment. For post-translational modifications, methods to enrich modified peptides from complex mixtures have played an important role. Chief among these is immunoaffinity enrichment, where antibodies directed against post-translational modifications (or remnants thereof) are used to capture analytes of interest for mass spectrometry analysis. To expand upon these methods, here we report on an automated PTMScan® immunoaffinity enrichment protocol, developed using the Phynexus MEA benchtop robot, for concurrent processing of up to twelve samples. System optimization has included interrogating the effects of peptide incubation, washing, and antibody-resin crosslinking on the sensitivity and specificity of this automated method. Using this technology in conjunction with Ubiquitin Remnant Motif (K-ε-GG), it is now possible to identify and quantify many >10,000 distinct ubiquitination events from cultured cells and tissue samples. This webinar will focus on the utility of the PTMScan method in early drug discovery and the future of automation in multiplexed analysis of cellular signaling.

During this webinar, viewers will learn about:

  • How changes in post-translational modification can be used to assess activation states of novel therapeutic targets;
  • Benchtop robot automation of the PTMScan® immunoaffinity enrichment protocol, enabling concurrent processing of 12 samples;
  • Utility of the PTMScan® method for early drug discovery, and the future of automation in multiplexed analysis of cellular signaling.

 

PTMScan® is a registered trademark of Cell Signaling Technology, Inc.

 

 

 


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
AUG 24, 2021 11:00 AM PDT
C.E. CREDITS
AUG 24, 2021 11:00 AM PDT
Date: August 24, 2021 Time: 11:00am (PDT), 1:00pm (EDT) Electron-based dissociation mechanisms have shown great promise for advanced characterization of biomolecules. However, routine adopti...
OCT 27, 2021 6:00 AM PDT
C.E. CREDITS
OCT 27, 2021 6:00 AM PDT
Date: October 27, 2021 Time: 6:00 AM PDT, 9:00 AM EDT Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such...
MAR 27, 2018 9:00 AM PDT

Proteomics profiling of post-translational modifications in early drug discovery



Show Resources
Loading Comments...
Show Resources